Johnson & Johnson announced sales of $16.6 billion for the fourth quarter of 2009, an increase of 9% as compared to the fourth quarter of 2008. Operational growth was 4.5% and currency contributed 4.5%. Domestic sales were up 2.6%, while international sales increased 15.6%, reflecting operational growth of 6.4% and a positive currency impact of 9.2%. Worldwide sales for the full-year 2009 were $61.9 billion, a decrease of 2.9% over 2008. Domestic sales declined 4.4%, while international sales declined 1.4%, reflecting operational growth of 3.9% and a negative currency impact of 5.3%.
“In a year of tremendous challenge, we maintained our long-term focus while delivering solid results—a great tribute to the employees of Johnson & Johnson,” said William C. Weldon, chairman and CEO, J & J. “We made important investments in acquisitions, strategic partnerships and launches of recently approved innovative products while preserving our financial flexibility to continue to invest in innovation. This positions us well for continued leadership and growth in global health care as we enter 2010.”
Worldwide consumer division sales of $15.8 billion for the full-year 2009 represented a decrease of 1.6% over the prior year. Domestic sales decreased 1.4%; international sales decreased 1.7%, which reflected operational growth of 4.7% and a negative currency impact of 6.4%.
Primary contributors to operational growth included Neutrogena, Aveeno and the Dabao skin care products and international sales of Listerine antiseptic mouthrinse.
The complete financial release is available here.
